Comparison of the growth hormone, IGF-1 and insulin in cerebrospinal fluid and serum between patients with motor neuron disease and healthy controls
- PMID: 17116217
- DOI: 10.1111/j.1468-1331.2006.01503.x
Comparison of the growth hormone, IGF-1 and insulin in cerebrospinal fluid and serum between patients with motor neuron disease and healthy controls
Abstract
Neurotrophic effects of the growth hormone (GH), insulin-like growth factor-1 (IGF-1) and insulin on the central nervous system have become more apparent in the past decade. In this study, we measured serum and cerebrospinal fluid (CSF) concentrations of GH, IGF-1 and insulin in 35 patients with motor neuron disease (MND) [24 patients with definite amyotrophic lateral sclerosis (ALS) and 11 patients with progressive bulbar palsy] and in 40 healthy controls. Levels of serum concentrations of GH and IGF-1 did not significantly differ between the MND patient group and the healthy controls, while the level of insulin was significantly decreased (P = 0.0033) in the MND patient group. However, levels of all three examined parameters in CSF were significantly lower in the MND group than in the healthy controls with the statistical significance for IGF-1 and insulin of P < 0.001. This finding has not been reported previously, and further investigations into its association with ALS should establish whether it can be used as an early marker of the disease, or whether it merely represents a consequence of ALS development.
Similar articles
-
The GH-IGF system in amyotrophic lateral sclerosis: correlations between pituitary GH secretion capacity, insulin-like growth factors and clinical features.Eur J Neurol. 2010 May;17(5):666-71. doi: 10.1111/j.1468-1331.2009.02896.x. Epub 2009 Dec 7. Eur J Neurol. 2010. PMID: 20002733
-
CSF glial markers correlate with survival in amyotrophic lateral sclerosis.Neurology. 2010 Mar 23;74(12):982-7. doi: 10.1212/WNL.0b013e3181d5dc3b. Neurology. 2010. PMID: 20308682
-
Cerebrospinal fluid insulin-like growth factor-1, insulin growth factor binding protein-2 or nitric oxide are not increased in MS or ALS.Acta Neurol Scand. 2004 May;109(5):337-41. doi: 10.1111/j.1600-0404.2004.00223.x. Acta Neurol Scand. 2004. PMID: 15080860
-
Neurotrophic and Neuroregenerative Effects of GH/IGF1.Int J Mol Sci. 2017 Nov 17;18(11):2441. doi: 10.3390/ijms18112441. Int J Mol Sci. 2017. PMID: 29149058 Free PMC article. Review.
-
Insulin-like growth factor system in amyotrophic lateral sclerosis.Endocr Dev. 2005;9:160-169. doi: 10.1159/000085764. Endocr Dev. 2005. PMID: 15879696 Review.
Cited by
-
Novel CSF biomarkers for frontotemporal lobar degenerations.Neurology. 2010 Dec 7;75(23):2079-86. doi: 10.1212/WNL.0b013e318200d78d. Epub 2010 Nov 3. Neurology. 2010. PMID: 21048198 Free PMC article.
-
Monomeric ß-amyloid interacts with type-1 insulin-like growth factor receptors to provide energy supply to neurons.Front Cell Neurosci. 2015 Aug 7;9:297. doi: 10.3389/fncel.2015.00297. eCollection 2015. Front Cell Neurosci. 2015. PMID: 26300732 Free PMC article.
-
Applying proteomics to the diagnosis and treatment of ALS and related diseases.Muscle Nerve. 2009 Nov;40(5):753-62. doi: 10.1002/mus.21488. Muscle Nerve. 2009. PMID: 19670321 Free PMC article. Review.
-
Hypothalamus and amyotrophic lateral sclerosis: potential implications in sleep disorders.Front Aging Neurosci. 2023 Jul 3;15:1193483. doi: 10.3389/fnagi.2023.1193483. eCollection 2023. Front Aging Neurosci. 2023. PMID: 37465321 Free PMC article. Review.
-
The protective effect of growth hormone on Cu/Zn superoxide dismutase-mutant motor neurons.BMC Neurosci. 2015 Feb 6;16(1):1. doi: 10.1186/s12868-015-0140-z. BMC Neurosci. 2015. PMID: 25655275 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
